Evaluation of this ER pathway assay on a large number of ER positive and negative breast cancer samples as well as three independent clinical patient cohorts treated with neoadjuvant hormonal therapy provided evidence that nuclear ER staining is required, but not sufficient, for ER pathway activity [1, 3]. Here, ESR1 is linked to breast cancer.